← All trials
NCT06380907
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2024
- Primary completion
- Feb 28, 2026
- Completion date
- Mar 31, 2026
- First posted
- Apr 24, 2024
- Last posted
- Nov 5, 2024
- Enrollment
- 250
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zai Lab Pty. Ltd.Lead sponsor
- Zai Lab Pty. Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.